Original Source(s)
Related Content
FDA clears targeted cholangiocarcinoma therapy
In the single-arm REFOCUS trial, 46% of patients responded to treatment, with a median response duration of 11.8 months.
September 24, 2026
-
2 min
APT may fall short in pulsatile tinnitus
Low sensitivity and specificity suggest a negative tracing should not deter further imaging evaluation.
October 9, 2026
-
3 min
Azithromycin uptake may reduce postcesarean infections
Trial evidence translated into wider clinical use as postpartum infection rates declined in US practice.
September 30, 2026
-
4 min
